Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Ocular Rosacea Treatments: Topical antimicrobials achieved a complete or partial response in 91% (n = 82/90) of patients, while oral antibiotics reached 89% (n = 525/580), and cyclosporine ophthalmic emulsion demonstrated an 87% response rate (n = 40/46). Combination treatments were also effective, yielding a response rate of 90% (n = 69/77).
• Dry Eye Disease Treatments: Restasis (cyclosporine ophthalmic emulsion) showed the highest efficacy for reducing Ocular Surface Disease Index (OSDI) scores, with an odds ratio of 4.82 (95% confidence interval (CI) 6.18 to 3.45). Zirun outperformed others in improving Schirmer's test scores (surface under the cumulative ranking curve (SUCRA) 73.9%), while TJ Cyporin was ranked highest for improving tear film break-up time (SUCRA 65.3%).
• There is no safety information available in the reviewed studies for cyclosporine ophthalmic emulsion or other treatments for ocular rosacea. For dry eye disease, Clacier had the lowest incidence of treatment-emergent adverse events, comparable to placebo, while no specific safety outcomes were mentioned for Restasis.
• There is no population types or subgroups information available in the reviewed studies.